Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Formulation and Characterization of Curcumin 12-Hydroxystearic Acid in Triacetin Organogel for Topical Administration

View through CrossRef
Background: Curcumin (CUR) and its derivatives have shown a wide variety of biological activities, such as anti-oxidant, anti-inflammatory, anti-tumor, antimicrobial and antiparasitic effects as well as for the treatment of skin diseases. Due to its physico-chemical limitations such as low aqueous solubility and low bioavailability, we developed curcumin organogel as a topical delivery system to overcome those limitations. The12-hydroxystearic acid (12-HSA) is well known as a low-molecular-weight organogelators (LMOGs) capable of gelling an organic liquid phase. Different concentrations of (12-HSA) in triacetin with 50 mg CUR were gelled and applied for various examinations: tabletop rheology, oil binding capacity, pH measurement, spreadability, in vitro drug release, antibacterial activity and oscillatory rheology studies. The results revealed that the organogels transition temperatures from solid to liquid were greater than the normal body temperature, this helped the organogels keep their shape; they had good spreadability,and the organogels pH levels were within the safe range for the skin . In vitro release data showed that 4% 12HSA+5%CUR +TA (4TA) gave us 100% release after 6 hours. The selected 4TA illustrated good viscoelastic properties in the amplitude sweep test and a frequency-independent as seen in the frequency sweep test. CUR has good antibacterial action against Staphylococcus aureus; Streptococcus pyrogen, Proteus mirabilis, and Escherichia coli, which prevail at the site of wound injury as this pointed out that 4TA organogel can be used for topical wound healing.
Title: Formulation and Characterization of Curcumin 12-Hydroxystearic Acid in Triacetin Organogel for Topical Administration
Description:
Background: Curcumin (CUR) and its derivatives have shown a wide variety of biological activities, such as anti-oxidant, anti-inflammatory, anti-tumor, antimicrobial and antiparasitic effects as well as for the treatment of skin diseases.
Due to its physico-chemical limitations such as low aqueous solubility and low bioavailability, we developed curcumin organogel as a topical delivery system to overcome those limitations.
The12-hydroxystearic acid (12-HSA) is well known as a low-molecular-weight organogelators (LMOGs) capable of gelling an organic liquid phase.
Different concentrations of (12-HSA) in triacetin with 50 mg CUR were gelled and applied for various examinations: tabletop rheology, oil binding capacity, pH measurement, spreadability, in vitro drug release, antibacterial activity and oscillatory rheology studies.
The results revealed that the organogels transition temperatures from solid to liquid were greater than the normal body temperature, this helped the organogels keep their shape; they had good spreadability,and the organogels pH levels were within the safe range for the skin .
In vitro release data showed that 4% 12HSA+5%CUR +TA (4TA) gave us 100% release after 6 hours.
The selected 4TA illustrated good viscoelastic properties in the amplitude sweep test and a frequency-independent as seen in the frequency sweep test.
CUR has good antibacterial action against Staphylococcus aureus; Streptococcus pyrogen, Proteus mirabilis, and Escherichia coli, which prevail at the site of wound injury as this pointed out that 4TA organogel can be used for topical wound healing.

Related Results

Nghiên cứu bào chế curcumin dạng phytosome và dạng PEG hóa
Nghiên cứu bào chế curcumin dạng phytosome và dạng PEG hóa
Curcumin có nhiều tác dụng dược lý quan trọng nhưng chưa được ứng dụng nhiều trên lâm sàng do sinh khả dụng thấp. Phytosome curcumin và PEG-CUR được nghiên cứu để tăng sinh khả dụn...
Synthesis, characterization and evaluation of antibacterial activity of copper(II)-curcumin complex against staphylococcus aureus
Synthesis, characterization and evaluation of antibacterial activity of copper(II)-curcumin complex against staphylococcus aureus
Curcumin, a phytochemical from turmeric, and its derivatives have been extensively investigated from both chemical and biological strategies. However, the main problem encountered ...
Abstract 1772: Circadian control of cell death in glioma cells treated with curcumin
Abstract 1772: Circadian control of cell death in glioma cells treated with curcumin
Abstract Treatments based on the phytochemical curcumin have much potential for use in cancer treatments because of their effects on a wide variety of biological pat...
Abstract 1856: Sustained release curcumin microparticles delay mammary tumorigenesis in BALB-neuT transgenic mice
Abstract 1856: Sustained release curcumin microparticles delay mammary tumorigenesis in BALB-neuT transgenic mice
Abstract This work examined the chemopreventive efficacy of curcumin delivered by poly(lactide-co-glycolide) (PLGA) microparticles in a HER-2 transgenic mouse mammar...
Curcumin (Turmeric): A Carcinogenic, Miscarriage and Cirrhosis Causing Agent
Curcumin (Turmeric): A Carcinogenic, Miscarriage and Cirrhosis Causing Agent
Background: Curcumin, a compound derived from the turmeric plant (Curcuma longa), has been historically used in Asian cuisine and traditional medicine. It is known for its anti-inf...
Abstract A76: Curcumin inhibits head and neck squamous cell carcinoma (HNSCC) migration
Abstract A76: Curcumin inhibits head and neck squamous cell carcinoma (HNSCC) migration
Abstract Purpose: Curcumin has been shown to inhibit HNSCC cell proliferation through the AKT/MTOR pathway. We wanted to study the biological effects of curcumin-ind...
Abstract 1739: Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma
Abstract 1739: Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma
Abstract Background: Patients with unresectable advanced hepatocellular carcinoma (HCC) are often treated with systemic therapies, and lenvatinib is currently used a...

Back to Top